Emergent BioSolutions (EBS) Cash & Current Investments (2010 - 2026)

Emergent BioSolutions' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $161.5 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 5.69% year-over-year to $161.5 million in Q1 2026; TTM through Mar 2026 was $161.5 million, a 5.69% increase from a year earlier, with the FY2025 full-year figure at $209.1 million, up 98.01% from the prior year.
• Cash & Current Investments declined to $161.5 million in Q1 2026 per EBS's latest filing, from $209.1 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $642.6 million in Q4 2022 and bottomed at $71.0 million in Q2 2024.
• The 5-year median for Cash & Current Investments is $161.5 million (2026), against an average of $226.6 million.
• Across the five-year window, Cash & Current Investments slumped 82.62% in 2023 and surged 281.69% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $642.6 million in 2022, then slumped by 82.62% to $111.7 million in 2023, then decreased by 5.46% to $105.6 million in 2024, then jumped by 98.01% to $209.1 million in 2025, then decreased by 22.76% to $161.5 million in 2026.
• Per Business Quant, the three latest EBS Cash & Current Investments figures stand at $161.5 million (Q1 2026), $209.1 million (Q4 2025), and $249.2 million (Q3 2025).